



11 September 2024

**Pro Rata Accelerated Non-Renounceable Entitlement Offer
Offer Document and Shareholder Access Information**

Lumos Diagnostics Holdings Limited (ASX: **LDX**) (the **Company**) announces that today, Wednesday 11 September 2024, is the Opening Date of the retail component of its pro rata accelerated non-renounceable entitlement offer (**Retail Entitlement Offer**), and that the Company will today issue relevant documents to Eligible Shareholders.

This announcement follows the Company's notification to the market on 4 September 2024 of the launch of the Institutional and Retail Entitlement Offer.

A copy of the relevant documents Eligible Shareholders are to receive are enclosed with this notice, comprising:

- Sample Letter to Eligible Shareholders;
- Offer Booklet; and
- Sample Retail Entitlement Offer Application Form.

Also accompanying this notice is a copy of the letter which will be dispatched today to Ineligible Shareholders.

Eligible Shareholders who have provided an email address for communications will receive an email containing a link to their individual Entitlement documents. Eligible Shareholders who have not provided an email address for communications will receive a hard copy personalised Covering Letter to their registered postal address, containing details of how to access their individual Entitlement documents.

The closing date of the Entitlement Offer is 5:00pm (AEST) on Wednesday, 2 October 2024. The Company reserves the right to vary the closing date without further notice.

Shareholders should consider the Offer Booklet in full before deciding whether to participate in the Retail Entitlement Offer.

Shareholders requiring information about the Retail Entitlement Offer may contact the Company Secretary Information Line on +61 3 9087 1598 or email cosec@lumosdiagnostics.com.

This announcement is authorised for release by the Lumos Board of Directors.

###

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Media Contact:

Haley Chartres – Australia

HACK Director

haley@hck.digital

+61 423 139 163

Investor Contact:

Jane Lowe

Managing Director, IR Department

ir@lumosdiagnostics.com

+61 411 117 774

Company Registered Office:

Lumos Diagnostics Holdings Ltd

Level 4, 96-100 Albert Rd

South Melbourne, VIC 3205

info@lumosdiagnostics.com

+61 3 9087 1598

Important Notices

This announcement is issued by Lumos Diagnostics Holdings Limited. This announcement is not a prospectus or offering document under Australian law or under any other law. It is for information purposes only and does not constitute an offer, invitation, solicitation, advice or recommendation to subscribe for, retain or purchase any entitlements or securities in Lumos Diagnostics Holdings Limited in any jurisdiction. This letter does not constitute financial product advice and does not and will not form any part of any contract for the acquisition of Lumos Diagnostics Holdings Limited ordinary shares.

Not for Distribution or Release in the United States

This letter does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or to, or for the account or benefit of, any person in the United States or in any other jurisdiction in which such an offer would be illegal. The New Shares have not been, nor will be, registered under the U.S. Securities Act of 1933 as amended (U.S. Securities Act) or under the securities laws of any state or other jurisdiction of the United States. The New Shares may not be issued to, purchased or traded by, or taken up by, any person in the United States or any person acting for the account or benefit of a person in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.